EUVIMEDEUVIMED entdecken
Übersichtsarbeit

RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy

Jiawei Xu, Xingyu Liu, Shuqin Wu, Deju Zhang, Xiao Liu, Panpan Xia, Jitao Ling, Kai Zheng, Minxuan Xu, Yunfeng Shen, Jing Zhang, Peng Yu

BioScience Trends · 2023

DOI: 10.5582/bst.2022.01473 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioScience Trends, 2023. Verfasst von Jiawei Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College / The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 149 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease globally and seriously increases the public health burden, affecting approximately one quarter of the world population. Recently, RNA binding proteins (RBPs)-related pathogenesis of MAFLD has received increasing attention. RBPs, vividly called the gate keepers of MAFLD, play an important role in the development of MAFLD through transcription regulation, alternative splicing, alternative polyadenylation, stability and subcellular localization. In this review, we describe the mechanisms of different RBPs in the occurrence and development of MAFLD, as well as list some drugs that can improve MAFLD by targeting RBPs. Considering the important role of RBPs in the development of MAFLD, elucidating the RNA regulatory networks involved in RBPs will facilitate the design of new drugs and biomarkers discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansAnimalsRNA, UntranslatedRNA-Binding ProteinsAlternative SplicingCytoplasm

Stichwörter der Autor:innen

RNA-RBP interactionRNAbinding protein (RBP)metabolic-associated fatty liver disease (MAFLD)non-alcoholic fatty liver disease (NAFLD)non-coding RNA

Substanzen

RNA, UntranslatedRNA-Binding Proteins

Autor:innen und Institutionen

  • The Second Clinical Medical College / The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
  • Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Hong Kong, China.
  • Department of Cardiology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
  • Medical Care Strategic Customer Department, China Merchants Bank Shenzhen Branch, Shenzhen, Guangdong, Guangdong, China.
  • Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Zitieren

APA

Xu, J., Liu, X., Wu, S., Zhang, D., Liu, X., Xia, P., Ling, J., Zheng, K., Xu, M., Shen, Y., Zhang, J., & Yu, P. (2023). RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy. BioScience Trends. https://doi.org/10.5582/bst.2022.01473

Vancouver

Xu J, Liu X, Wu S, Zhang D, Liu X, Xia P, et al. RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy. BioScience Trends. 2023. doi:10.5582/bst.2022.01473

BibTeX
@article{Xu2023,
  author = {Xu, Jiawei and Liu, Xingyu and Wu, Shuqin and Zhang, Deju and Liu, Xiao and Xia, Panpan and Ling, Jitao and Zheng, Kai and Xu, Minxuan and Shen, Yunfeng and Zhang, Jing and Yu, Peng},
  title = {RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy},
  journal = {BioScience Trends},
  year = {2023},
  doi = {10.5582/bst.2022.01473}
}
Kostenlos starten →